December 15, 2025-
- Acquisition of SpectraWAVE’s next-generation technologies including HyperVue (TM) Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1 (TM)-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1]
- SpectraWAVE’s technologies have the potential to significantly increase adoption of coronary intravascular imaging and physiological assessment, especially when combined with Philips’ industry-leading Azurion image-guided therapy platform, supporting better outcomes [2] for more cardiac patients
- Acquisition will expand Philips’ existing intravascular imaging and physiological assessment device portfolio, featuring Eagle Eye Platinum digital IVUS and OmniWire iFR technology, to create a comprehensive offering in intravascular imaging and physiology solutions
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging [3]. SpectraWAVE’s intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide [4]. SpectraWAVE, based in Bedford, Massachusetts, was founded in 2017 and currently employs more than 70 people.
“Our global leadership in image guided therapy is driven by deep clinical collaboration combined with our latest technology insights across hardware, software and AI, to innovate interventional procedures for better and more patient impact. Our world-class portfolio integrates interventional systems and devices into one platform, Azurion, serving patients worldwide.
“We are doubling down on image-guided therapy and expanding our portfolio in the coronary intervention segment with the addition of SpectraWAVE’s AI-powered innovations in high-definition intravascular imaging and angio-based physiological assessment, enabling us to deliver better care for more people,” said Roy Jakobs, CEO of Royal Philips.
Percutaneous coronary interventions are minimally invasive procedures that leverage intravascular imaging and physiological assessment to treat coronary artery disease. A significant and growing body of evidence shows that the use of intravascular imaging and physiological assessment technologies significantly improves patient outcomes for percutaneous coronary interventions [5]. With its industry-leading Azurion image-guided therapy platform, integrated with its expanding portfolio of advanced diagnostic and treatment devices, Philips is driving the adoption of advanced healthcare technology to treat a growing and increasingly complex patient population.
“Philips shares our deep conviction that the convergence of intravascular imaging, coronary physiology and AI can fundamentally improve how every patient with coronary disease is treated. This partnership allows us to integrate and scale HyperVue and X1-FFR into the world’s leading image-guided therapy ecosystem, expanding choice for clinicians and supporting more consistent, high-quality care for the millions of patients who depend on coronary intervention each year,” said Eman Namati, PhD, CEO of SpectraWAVE.
“With today’s announcement we continue to expand the role of minimally invasive image guided therapy procedures, which are associated with better patient outcomes and improved cost-effectiveness [6][7]. The acquisition of SpectraWAVE’s next-generation technologies for coronary intravascular imaging and physiological assessment mark a significant step in expanding our portfolio with breakthrough, AI-powered technologies that help clinicians decide, guide, treat and confirm treatment in one setting,” said Bert van Meurs, Chief Business Leader Image Guided Therapy at Philips.
Expanding clinician choice and integrating AI across its coronary portfolio
SpectraWAVE’s HyperVue Imaging System is an intravascular imaging platform that combines DeepOCT (next generation comprehensive optical coherence tomography) and NIRS (near-infrared spectroscopy) into the Enhanced Vascular Imaging (EVI) novel imaging segment to provide detailed structural and compositional images of the coronary arteries during percutaneous coronary interventions, with rapid setup, acquisition, and automated AI image analysis. Combined with Philips’ Eagle Eye Platinum digital IVUS and IntraSight technologies, HyperVue will expand clinicians’ intravascular imaging toolbox – IVUS, DeepOCT, NIRS, and wire and angio-derived physiology – all orchestrated through integrated systems to tailor guidance to each patient and lesion.
SpectraWAVE’s X1-FFR is an angiography-derived, AI-enabled physiology solution that calculates Fractional Flow Reserve (FFR) from a single coronary angiogram, providing a non-invasive ischemia assessment and turning routine X-ray images into coronary physiology data for simplified percutaneous coronary intervention workflows. X1-FFR complements Philips OmniWire iFR technology by extending physiologic guidance to wire-free scenarios and equipping clinicians with a versatile toolkit to broaden the adoption of coronary physiology in daily practice.
Philips offers one of the most comprehensive image-guided therapy portfolios in the industry, providing solutions for visual guidance during minimally invasive procedures and image-guided therapy devices designed to enhance procedural efficiency and improve patient outcomes. At the heart of this portfolio is Azurion, Philips’ next-generation platform that brings advanced interventional tools together in a single, intuitive environment supporting a wide range of procedures across interventional cardiology, interventional radiology, neuroradiology and vascular surgery. Introduced in 2017, Philips Azurion is used to treat more than 7.6 million patients each year in over 80 countries.
Financial terms of the agreement are not disclosed.
